Drotrecogin alfa (activated) (LY203638) exploratory, safety study, multi-center, randomized, placebo-controlled, dose escalating study design, comparing a standard therapy (enoxaparin sodium) for submassive pulmonary embolism to a combined therapy of drotrecogin alfa (activated) plus enoxaparin sodium.

Trial Profile

Drotrecogin alfa (activated) (LY203638) exploratory, safety study, multi-center, randomized, placebo-controlled, dose escalating study design, comparing a standard therapy (enoxaparin sodium) for submassive pulmonary embolism to a combined therapy of drotrecogin alfa (activated) plus enoxaparin sodium.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2009

At a glance

  • Drugs Drotrecogin alfa; Enoxaparin sodium
  • Indications Pulmonary embolism
  • Focus Adverse reactions
  • Most Recent Events

    • 14 May 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top